AstraZeneca’s Farxiga Flies Across $1bn Barrier
Stellar Sales Of SGLT2 Inhibitor
First-quarter sales jumped by 56% to $11.39bn at AstraZeneca and while its COVID-19 products brought in $1.6bn, it was the performance of the diabetes, heart failure and chronic kidney disease drug Farxiga that impressed most.
You may also be interested in...
AstraZeneca’s Triple Regulatory Wins For Enhertu, Tezspire And Ultomiris Herald Sales Boost
The major has won US priority review for a commercially crucial label expansion of its breast cancer drug Enhertu while Tezspire and Ultomiris attracted positive CHMP opinions across the Atlantic.
Jardiance, Trajenta Wins: Boehringer Takes Rough With Smooth In India
Boehringer Ingelheim tackles infringement activity pertaining to Trajenta and Jardiance in India, at least for now, but more action appears to be in the wings. The private German group remains confident that Jardiance will retain its preferred treatment choice status in the country for type 2 diabetes - but can the blockbuster therapy shake up the heart failure segment as well?
Europe’s Big Pharma Players Begin Tricky 2022 In Style
Big pharma players have embraced a tricky operating environment in 2022 so far, treading a tightrope with political and financial challenges impacting their decision making and threatening to blow them off balance. However, what is not in doubt is the healthy growth experienced by those companies based around mainland Europe and the UK.